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INTRODUCTION 
Type 1 diabetes (T1D) is an organ-specific autoimmune
disease that is characterized by infiltration of lymphocytes
into the pancreatic islets and pancreas-specific autoantibod-
ies in the serum (1). A variety of genetically predisposed fac-
tors and contributing factors have been known to influence
the pathogenesis of T1D. Some evidence has suggested that
the susceptible genes to T1D are associated with the ampli-
fication of the immune response and the rate of progression
of the disease; the role of these genes appear to be more impor-
tant during childhood than during adult life (2). 
The association of HLA alleles and the development of T1D
has been shown by studies on diverse ethnic groups. How-
ever, a genetic predisposition solely conferred by the HLA is
not sufficient to explain the mechanism that leads to the devel-
opment of T1D. Therefore, it has been hypothesized that sev-
eral genes are involved in the development of T1D (3). 
The cytotoxic T lymphocyte antigen-4 gene (CTLA4) and
the gene encoding CD28 have been mapped to chromosome
2q33. CTLA-4 is a glycoprotein receptor expressed on acti-
vated T cells and CD28 is involved in the regulation process
of the activation of T cells by antigen-presenting cells and
subsequent cellular immunity (4). CTLA4 has been consid-
ered to be a permissive candidate gene involved in the etiol-
ogy of autoimmune diseases; this is because CTLA-4 plays a
role in the regulation of the activation of T cells and as well
as T cell and B cell interactions (5). 
According to prior studies on the association of the devel-
opment of various autoimmune diseases and the CTLA4 gene,
the 49 A/G polymorphism in CTLA4 exon 1 has been report-
ed to be involved in the development of Graves’ disease (6),
Hashimoto thyroiditis (7), a portion of Addison’s disease and
rheumatoid arthritis (8). A significant association of T1D with
the CTLA4 polymorphisms was reported by Nistico et al. (9)
for the first time; this association has been additionally report-
ed by other studies in a variety of ethnic groups (10, 11). How-
ever, in studies conducted in Japan (12) and other countries
(13, 14), the association of the CTLA4 polymorphisms with
the development of T1D has not been confirmed. 
The primary purpose of this study was to investigate whe-
ther the CTLA4 gene was associated with the development
of T1D in Korean children and adolescents. Furthermore,
we studied whether interactions between the CTLA4 gene
and susceptible HLA class II alleles had a role in the patho-
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Association of Cytotoxic T Lymphocyte Antigen-4 Gene Polymorphisms
and HLA Class II Alleles with the Development of Type 1 Diabetes 
in Korean Children and Adolescents
We studied the association of cytotoxic T lymphocyte antigen-4 gene (CTLA4) poly-
morphisms with the development of type 1 diabetes (T1D) in Korean children and
adolescents. A total of 176 Korean subjects (92 females and 84 males) with child-
hood-onset T1D were studied. The A/G polymorphism at position 49 in CTLA4 exon
1 and the C/T polymorphism at position -318 in the CTLA4 promoter were analyzed
by PCR-RFLP methods. The genotype and allele frequencies of the CTLA4 poly-
morphisms in the T1D patients were not different from those in the controls. These
polymorphisms were not associated with the clinical characteristics or the develop-
ment of autoimmune thyroid disease in the T1D patients. The frequency of the A
allele was significantly higher in the patients that did not have two out of the three
susceptible HLA-DRB1 alleles, which were DRB1*0301, *0405 and *09012, com-
pared to the controls (P<0.05). These results suggest that CTLA4 polymorphisms
do not directly confer any susceptibility to T1D. However, a CTLA4-mediated sus-
ceptibility effect on the development of T1D might be significant in children and ado-
lescents that do not have susceptible HLA class II alleles.
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MATERIALS AND METHODS
This study included 176 patients (92 females, 84 males)
with T1D, who were diagnosed during childhood and ado-
lescence (mean age, 7.5±4.0 yr) from 1992 to 2002 at dia-
betes clinic of Seoul National University Children’s Hospital.
In addition, 90 healthy individuals were recruited as a con-
trol group. The study was explained to all patients, and their
written consent was obtained. The diagnosis of T1D was based
on the blood glucose level according to the World Health
Organization diagnostic guidelines, clinical symptoms, abso-
lute insulin-dependency, and pancreas-specific autoantibodies.
We reviewed the clinical characteristics, such as diabetic
ketoacidosis at the initial presentation, age of onset, family
history of T1D, pubertal status at the onset of diabetes, and
presence of concomitant autoimmune thyroid disease to de-
termine whether there was an association between the CTLA4
polymorphisms and the clinical characteristics. Among the
study subjects, there were 31 patients (17.6%) with autoim-
mune thyroid disease that were diagnosed by thyroid func-
tion tests, anti-thyroid autoantibodies, and/or TSH receptor
stimulating antibodies. 
Genomic DNA was extracted from peripheral mononu-
clear cells using the Wizard DNA purification kit (Promega,
Maison, WI, U.S.A.), and quantified by spectrophotometer.
HLA-DRB1 alleles were analyzed by grouping of DRB1 using
a Dynal RELI SSO HLA-DRB1 typing kit (Dynal Biotech
Inc., Lake Success, NY, U.S.A.) and primers described pre-
viously (15). Each HLA-DRB1 allele was determined by the
single strand conformation polymorphism (SSCP) method.
HLA-DQB1 alleles were analyzed by applying PCR-RFLP
and PCR-SSCP methods as described previously (16). The
subjects were classified according to the known susceptible
DRB1 alleles (17). 
For the analysis of the A/G polymorphism at position 49
in the CTLA4 exon 1, the PCR-RFLP method was used as
described previously (7). The primers used were 5′ -GCTC-
TACTTCCTGAAGACCT-3′ (forward) and 5′ -AGTCTCA-
CTCACCTTTGCAG-3′ (reverse). Amplified samples were
digested with the specific restriction enzyme BbvI (New Eng-
land BioLabs, Beverly, MA, U.S.A.) at 37℃ for 2 hr, elec-
trophoresed on a 3% agarose gel for 30 min, stained with
ethidium bromide, and evaluated. A 162 bp band was deter-
mined to be the A allele and the 88 bp and 74 bp bands were
determined to be the G allele. 
The C/T polymorphism at position -318 in the CTLA4
promoter was analyzed by PCR-RFLP methods using known
primers 5′ -AAATGAATTGGACTGGATGGT-3′ (forward)
and 5′ -TTACGAGAAAGGAAGCCGTG-3′ (reverse) as des-
cribed previously (18). The amplified DNA products were
treated with the MseI restriction enzyme (New England Bio-
Labs) at 37℃ for 2 hr. The formation of 132/115 bp frag-
ments was determined to be the T allele and the detection of
the complete 247 bp fragment was identified as the C allele. 
The measured values are presented as mean±standard devi-
ation. The comparisons of the HLA genotypes of the patients
and the controls were performed using the two-tailed Fisher’s
exact test. The corrected P value (Pc) was obtained by multi-
plying the number of all genotypes included. The odds ratio
(OR) was calculated by the Woolf method, and the 95% con-
fidence interval (CI) was applied. For the cases with 0 vari-
ables, a Haldane’s modification method was used. A P<0.05
was considered statistically significant. 
RESULTS
The genotype and allele frequencies of the CTLA4 exon 1
polymorphism in T1D patients were not different from those
in the control subjects (Table 1). The distribution of the CTLA4
exon 1 polymorphsims in patients with T1D and autoim-
mune thyroid disease (n=31) was not different from that in
the control subjects. There was no relationship of the CTLA4
exon 1 polymorphism with the clinical characteristics of the
patients, such as presence of ketoacidosis, age of disease onset,
gender, pubertal status at initial presentation, and concomi-
tant autoimmune thyroid disease. 
We analyzed the distribution of the CTLA4 exon 1 poly-
Data are n (%).







Type 1 diabetes 176 24 (13.6) 58 (33.0) 94 (53.4) 106 (30.1) 246 (69.9)
With AITD 31 5 (16.1) 10 (32.3) 16 (51.6) 20 (32.3) 42 (67.7)
DKA at diagnosis 43 6 (14.0) 12 (27.9) 25 (58.1) 24 (27.9) 62 (72.1)
SMR at diagnosis
Prepubertal 143 22 (15.3) 46 (32.2) 75 (52.4) 90 (31.5) 196 (68.5)
In puberty 33 2 (6.1) 12 (36.4) 19 (57.6) 16 (24.2) 50 (75.8)
Controls 90 13 (14.4) 31 (34.4) 46 (51.1) 57 (31.7) 123 (68.3)
Table 1. Distribution of the polymorphism at position 49 in exon 1 of the CTLA4 gene in patients with type 1 diabetes and controls1006 M.H. Jung, J. Yu, C.H. Shin, et al.
morphism according to the presence or absence of suscepti-
ble HLA-DRB1 alleles (DRB1*0301, *0405 and *09012).
In the patients without the HLA-DRB1*0301 allele, the fre-
quency of the A allele was significantly higher than in the
control subjects (43.6% vs. 31.7%; P<0.05). 
We analyzed the distribution of the CTLA4 exon 1 poly-
morphism in a subgroup of patients that did not have two out
of the three susceptible DRB1 alleles. According to the anal-
ysis of the genotype frequency, the frequency of the A/A geno-
type in the patients without the DRB1*0301 and *09012
alleles was significantly higher compared to the control sub-
jects (36.0% vs. 14.4%; P<0.05) (Table 2). According to
the analysis of the allele frequency, the frequency of the A
allele in the patients without the DRB1*0301 and *0405
alleles was significantly higher than in the control subjects
(45.5% vs. 31.7%; P<0.05). In addition, the frequency of
the A allele was significantly higher in the patients without
the DRB1*0301 and *09012 alleles (52.0% vs. 31.7%; P<
0.01), and the patients without the DRB1*0405 and *09012
alleles (54.2% vs. 31.7%; P<0.05), compared to the control
subjects. 
The genotype and allele frequencies of the CTLA4 pro-
moter polymorphism were not different in the comparison
between the T1D patients and the control subjects (Table 3).
The distribution of the CTLA4 promoter polymorphism in
patients with both T1D and autoimmune thyroid disease
was not different from that in the control subjects. When the
patients were divided into subgroups based on the presence
of the susceptible HLA-DRB1 alleles, the distribution of the
CTLA4 promoter polymorphism was not different in the
patients and the control subjects.
DISCUSSION
It has been reported that the intracellular transduction sig-
nals formed by the complex of T cell receptor molecules and
CTLA-4 molecules suppress the activation of T cells (19). The
CTLA-4 molecule encodes the T cell receptor that plays a role
in the control of the proliferation of T cells, as well as medi-
ating apoptosis of T cells. Therefore, it has been considered
to be a strong candidate molecule involved in the develop-
ment of T cell-mediated autoimmune disease. However, the
functional relationship of the CTLA-4 protein with human
disease has not been elucidated to date. 
The distribution of the CTLA4 exon 1 polymorphism
among Asians and Caucasians shows a clear difference. The
frequency of the G allele of CTLA4 exon 1 has been report-
ed to be 68% among Koreans (20), 57.5% (21) and 63% (22)
among Japanese, and 34.2% (10) and 36% (7) among Cau-
casians. On the other hand, the frequency of the T allele in
the CTLA4 promoter region has been reported to be 7-14%
Data are n (%).
*P<0.05, OR=3.33 (95% CI 1.21-9.11) vs. controls; 
� P<0.05, OR=1.80 (95% CI 1.01-3.21) vs. controls; 
� P<0.01, OR=2.34 (95% CI 1.24-4.42) vs. con-
trols; 







DRB1*0301(-)/0405(-) 33 8 (24.2) 14 (42.4) 11 (33.3) 30 (45.5)
� 36 (54.5)
DRB1*0301(-)/09012(-) 25 9 (36.0)* 8 (32.0) 8 (32.0) 26 (52.0)
� 24 (48.0)
DRB1*0405(-)/09012(-) 12 3 (25.0) 7 (58.3) 2 (16.7) 13 (54.2)
� 11 (45.8)
Controls 90 13 (14.4) 31 (34.4) 46 (51.1) 57 (31.7) 123 (68.3)








Type 1 diabetes 176 140 (79.5) 34 (19.3) 2 (1.1) 314 (89.2) 38 (10.8)
With AITD 31 25 (80.6) 6 (19.4) 0 56 (90.3) 6 (9.7)
DKA at diagnosis 43 33 (76.7) 9 (20.9) 1 (2.3) 75 (87.2) 11 (12.8)
SMR at diagnosis
Prepubertal 143 113 (79.0) 28 (19.6) 2 (1.4) 254 (88.8) 32 (11.2)
In puberty 33 27 (81.8) 6 (18.2) 0 60 (90.9) 6 (9.1)
Controls 90 71 (78.9) 17 (18.9) 2 (2.2) 159 (88.3) 21 (11.7)
Table 3. Distribution of the C/T polymorphism at position -318 in the promoter of the CTLA4 gene in patients with type 1 diabetes and
controls
Data are n (%).
AITD, autoimmune thyroid disease; DKA, diabetic ketoacidosis; SMR, sexual maturity rating.
PatientsAssociation of CTLA-4 Gene Polymorphisms with Type 1 Diabetes  1007
among Asians and Caucasians (23), without a marked eth-
nic difference noted to date. 
Our results showed that the distribution of the CTLA4
exon 1 polymorphism and the the CTLA4 promoter poly-
morphism in patients with T1D were not different from those
in control subjects. Recent studies on the association of the
CTLA4 polymorphisms and susceptibility to T1D in vari-
ous ethnic populations showed inconsistent results. Accord-
ing to the studies that included Japanese populations, the
distribution of the CTLA4 exon 1 polymorphisms in patients
with T1D was not different from that in normal individuals
(21, 22). By contrast, Steck et al. (24) observed that the fre-
quency of the C/C genotype at position -318 in the CTLA4
promoter was significantly lower in patients with T1D com-
pared to controls, and they concluded that this polymorphism
was associated with T1D. 
Meanwhile, a clear association was detected between the
CTLA4 genotype and the degree of expression of the CTLA-
4 protein (25). According to this study, in individuals with
thymidine (-318T) in CTLA4 promoter region, after the stim-
ulation of cells, the expression of CTLA-4 on the cell surface
and the expression of CTLA4 mRNA in unstimulated cells
were significantly increased. In a recent study, Ueda et al. (26)
reported that a reduction in the level of a soluble isoform of
CTLA-4 (sCTLA-4) mRNA, associated with the disease-sus-
ceptible haplotype of CTLA4, could lead to reduced blocking
of CD80/CD86, causing increased activation through CD28,
or to less stimulation of CD80/CD86. In order to verify the
association of the CTLA4 polymorphisms with the patho-
genesis of T1D, distinctive difference in the distribution of
CTLA4 genotypes between patients and controls should be
identified. However, this has not been consistently demon-
strated to date. 
The results of recent studies suggest that CTLA4 polymor-
phisms are associated with the clinical characteristics of pati-
ents with T1D. Abe et al. (22) reported a patient group with
initial diabetic ketoacidosis and positive for the ICA512 anti-
body had a different distribution of the CTLA4 polymor-
phisms compared to control subjects. Other studies showed
that the frequency of the G allele of CTLA4 exon 1 was high-
er in patients with a high titer of GAD antibodies and high
residual function of β -cells compared to the control subjects
(21, 27). Such results may indicate that CTLA4 polymor-
phisms are involved in the more potent immune response
and specific clinical characteristics of patients with T1D. In
addition, Takara et al. (28) reported that the frequency of the
G allele of CTLA4 exon 1 was significantly higher in patients
with both T1D and autoimmune thyroid disease concomi-
tantly, compared to the controls. However, the results of our
study showed no association of CTLA4 polymorphisms and
the clinical characteristics of patients with T1D. Therefore,
further study is needed to clarify the association of CTLA4
polymorphisms with specific clinical characteristics of patients
with T1D. 
We analyzed the relationship between the CTLA4 exon 1
polymorphism and HLA-DRB1 alleles to determine whether
their interactions had a role in the pathogenesis of T1D. In
the diabetic patients that did not have two out of the three
susceptible DRB1 alleles, that is DRB1*0301, *0405 and
*09012, the frequency of the A allele of CTLA4 exon 1 was
significantly higher than that in the control subjects. This
finding suggests that the CTLA4 polymorphism was associ-
ated with the development of T1D only in the patients that
had no specific susceptible HLA-DRB1 alleles. 
There have been several reports regarding the association
of CTLA4 polymorphisms with HLA-DRB1 allele in the
pathogenesis of T1D. Djilali-Saiah et al. (29) reported that in
diabetic patients with the DR4 haplotype, the frequency of
the G allele of CTLA4 exon 1 was significantly higher. Mochi-
zuki et al. (21) reported that in children with T1D that did
not have susceptible DRB1*0405 allele, there was a higher
frequency of G allele of CTLA4 exon 1 compared to normal
children. On the other hand, Donner et al. (30) conducted a
combined transmission analysis of the CTLA4 polymorphisms
and HLA DQA1-DQB1 and reported that in patients with
T1D that had susceptible haplotypes, such as HLA DQA1*
0301-DQB1*0302 or DQA1*0501-DQB1*0201, the pro-
tective 84-bp allele of the (AT)n repeat of CTLA4 polymor-
phism was not protective against the development of T1D.
Therefore, when patients do not have susceptible HLA class
II alleles, the CTLA4 polymorphism appears to play some
role in the pathogenesis of T1D.
Mochizuki et al. (21) explained that the sensitivity of T-cell
activation to the CTLA4 mediated pathway after the initia-
tion of the T-cell receptor and DR molecule-antigen complex
may be decreased in the absence of susceptible HLA-DRB1
alleles. However, because the distribution of both CTLA4
and the HLA class II alleles vary in different ethnic popula-
tions, further study of the association of these two genes is
needed. 
In conclusion, the results of this study suggest that HLA-
DRB1 and DQB1 alleles play a primary role in pathogene-
sis of T1D and that the CTLA4 exon 1 polymorphism is a
genetic factor that mediates the disease associated suscepti-
bility in patients that do not have specific susceptible HLA
class II alleles. This concept requires further study and con-
firmation among different ethnic groups. 
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